An observational study in Infective Endocarditis, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Infective endocarditis (IE) is a severe condition associated with high mortality. Due to the relative low prevalence of IE, prospective data are lacking and current guidelines are mostly based on expert consensus with low level of evidence. IE is also associated with severe complications especially strokes that occur in about one third of the patients.
In order to improve the management and the prognosis of IE, clinical data from larges prospective cohort studies are needed.
The study will take place at the Cardiology institute of the Pitié-Salpêtrière hospital. All patients referred to this tertiary care center for IE management will be included.
The characteristics of the patients (demographics, clinical, laboratory, and imaging data) at the time of IE diagnosis and during the follow-up will be collected. The patients will be followed up to 10 years after inclusion.
173 studies on the registry are indexed under Endocarditis; 57 are open to participants now.
This study's planned enrollment of 700 is above the median of 225 across 82 observational studies indexed under Endocarditis.
Browse Endocarditis studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All the patients with IE admitted at Cardiology institute of the Pitié-Salpêtrière hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All-cause in hospital mortality
All-cause mortality during the length of hospital stay
Time frame: up to 90 days
All-cause mortality
mortality at longest follow-up
Time frame: an average of 10 years
symptomatic or asymptomatic systemic embolism
symptomatic or asymptomatic systemic embolism confirmed by any type of imaging during initial hospitalization
Time frame: up to 90 days after inclusion
Association between coagulation biomarkers (D-dimer, fibrin monomer, circulating anticoagulant, von Willebrandt factor (VWF) antigen level, von Willebrandt factor (VWF) activity) assessed at the inclusion and the presence of systemic embolism
Association between coagulation biomarkers (D-dimer, fibrin monomer, circulating anticoagulant, von Willebrandt factor (VWF) antigen level, von Willebrandt factor (VWF) activity) assessed at the inclusion and the presence of systemic embolism at the admission Initial Hospitalization
Time frame: inclusion
Association between coagulation biomarkers (D-dimer, fibrin monomer, circulating anticoagulant, von Willebrandt factor (VWF) antigen level, von Willebrandt factor (VWF) activity) assessed at the inclusion and the presence of systemic embolism
Association between coagulation biomarkers(D-dimer, fibrin monomer, circulating anticoagulant, von Willebrandt factor (VWF) antigen level, von Willebrandt factor (VWF) activity) assessed at the inclusion and the presence of systemic embolism within 90 days after admission
Time frame: up to 90 days after inclusion
heart failure, intracranial hemorrhage, or false vascular aneurysm during hospitalization
Occurrence of heart failure, intracranial hemorrhage, or false vascular aneurysm during the length of hospital stay
Time frame: up to 90 days after inclusion
Stroke
Stroke during the length of hospital stay
Time frame: 90 days after inclusion
composite criteria of stroke, Intracranial hemorrhage, hospitalization due to cardiovascular cause or IE recurrence
Occurrence of a composite criteria of stroke, Intracranial hemorrhage, hospitalization due to cardiovascular cause or IE recurrence at one year
Time frame: 1 year after inclusion
composite criteria of stroke, Intracranial hemorrhage, hospitalization due to cardiovascular cause or IE recurrence
Occurrence of a composite criteria of stroke, Intracranial hemorrhage, hospitalization due to cardiovascular cause or IE recurrence at the longest follow-up
Time frame: through study completion, an average of 10 years
composite criteria of all-cause mortality, stroke or intracranial hemorrhage, severe hemorrhage as defined by BARC score ≥ 3
on-year composite criteria of all-cause mortality, stroke or intracranial hemorrhage, severe hemorrhage as defined by BARC score ≥ 3
Time frame: 1 year after inclusion
composite criteria of all-cause mortality, stroke or intracranial hemorrhage, severe hemorrhage as defined by BARC score ≥ 3
Occurrence of a composite criteria of all-cause mortality, stroke or intracranial hemorrhage, severe hemorrhage as defined by BARC score ≥ 3 at the longest follow-up
Time frame: through study completion, an average of 10 years
Association between occurrence of systemic embolism and the composite criteria of all-cause mortality, stroke or intracranial hemorrhage, severe hemorrhage as defined by BARC score ≥ 3
Association between occurrence of systemic embolism and the composite criteria of all-cause mortality, stroke or intracranial hemorrhage, severe hemorrhage as defined by BARC score ≥ 3 at one year
Time frame: 1 year after inclusion
Occurrence of contrast-associated acute kidney injury during the length of hospital stay
rise of serum creatinine \> 26.5 mcmol/L or \> 50% elevation from baseline over the course of hospitalization
Time frame: up to 90 days after inclusion
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2020 (actual). Primary completion is estimated for Sep 2040, 240 months after the start.
Of 36 observational studies under Endocarditis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 36. This study's planned 240 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →